Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today confirmed that the ongoing conflict in Iran and broader Middle East geopolitical tensions have not had a material impact on the Company's operations, supply chain, or business performance. The Company also noted continued record revenue momentum and reaffirmed that its U.S. expansion, including the rollout of NOOR collagen, remains on track.
Geopolitical Resilience Underpins Global Platform
Cosmos Health operates through a diversified international platform spanning Europe, North America, and other key regions. The conflict in the Middle East and recent geopolitical developments have had a negligible impact on the Company's operations. Management expects strong growth momentum to continue as the Company advances toward sustained profitability.
Record Revenue Momentum Continues
The Company's most recently reported quarter, Q3 2025, marked a new all-time high, with revenue reaching $17.1 million, a 38% increase year-over-year. Gross profit more than doubled, increasing 116% to $2.6 million, with a record gross margin of 15.21%, while Adjusted EBITDA improved 74%. Cash position strengthened to $4.63 million, up from $0.66 million at the end of Q2 2025.
This record-setting momentum has continued into subsequent periods. More detailed financial information will be provided in conjunction with the Company's fourth quarter and full-year 2025 results, expected shortly.
NOOR U.S. Expansion Accelerating
Sales of Sky Premium Life NOOR collagen in the United States are already underway, with the product manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities, underscoring the Company's commitment to regulatory excellence and product integrity while mitigating tariff exposure and cross-border logistical risks.
The Company anticipates gross margins of approximately 75% from its U.S. operations, with NOOR collagen alone projected to generate more than $12 million in revenue within the next 12 months, positioned to benefit from the U.S. nutraceuticals market, valued at $163.7 billion in 2024 and projected to grow at a 6.2% CAGR through 2030, according to Grand View Research.